Fulgent Genetics (FLGT) CFO has 2,747 shares withheld for RSU taxes

Rhea-AI Filing Summary

Fulgent Genetics, Inc. CFO and Treasurer Paul Kim reported a routine tax-related share disposition. On April 26, 2026, 2,747 shares of common stock were withheld to satisfy tax withholding obligations arising from the vesting of previously assumed restricted stock units under a prior merger agreement. Following this withholding, Kim directly holds 365,800 shares of Fulgent common stock, indicating he retained a substantial equity position and did not report an open-market sale in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kim Paul

Role CFO and Treasurer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	2,747	$16.31	$45K

Holdings After Transaction: Common Stock — 365,800 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Tax-withheld shares: 2,747 shares Withholding reference price: $16.31 per share Shares held after transaction: 365,800 shares +1 more

4 metrics

Tax-withheld shares 2,747 shares Common stock withheld for tax obligations on RSU vesting

Withholding reference price $16.31 per share Value used for 2,747 withheld common shares

Shares held after transaction 365,800 shares Direct Fulgent Genetics common stock holdings post-transaction

Transaction date April 26, 2026 Date of tax-withholding disposition reported on Form 4

Key Terms

restricted stock units, tax withholding obligations, Agreement and Plan of Merger, Form 4

4 terms

restricted stock units financial

"tax withholding obligations that arose upon the vesting of certain restricted stock units assumed"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"The shares were withheld from the reporting person to satisfy the tax withholding obligations"

Agreement and Plan of Merger financial

"assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022"

An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.

Form 4 regulatory

"These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Paul

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CALIFORNIA 91731

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and Treasurer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/26/2026		F		2,747(1)	D	$16.31	365,800	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.

	/s/ Paul Kim	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Fulgent Genetics (FLGT) report for CFO Paul Kim?

Fulgent Genetics reported that CFO Paul Kim had 2,747 common shares withheld to cover tax obligations from restricted stock unit vesting. This was recorded as a tax-withholding disposition, not an open-market sale, and is a common mechanism for handling equity award tax liabilities.

How many Fulgent Genetics (FLGT) shares were involved in the tax withholding?

The filing shows 2,747 Fulgent Genetics common shares were withheld at $16.31 per share. These shares satisfied tax withholding obligations triggered when certain restricted stock units vested, reflecting a mechanical tax event rather than a discretionary stock market transaction by the executive.

How many Fulgent Genetics (FLGT) shares does CFO Paul Kim hold after this Form 4?

After the tax-withholding transaction, CFO Paul Kim directly holds 365,800 Fulgent Genetics common shares. This post-transaction figure, reported in the Form 4, shows he maintains a significant ongoing equity stake in the company despite the small number of shares withheld for taxes.

Was the Fulgent Genetics (FLGT) CFO’s Form 4 transaction an open-market sale?

No, the Form 4 describes a tax-withholding disposition, not an open-market sale. Shares were surrendered to satisfy tax obligations from vesting restricted stock units, a standard administrative process often used so executives do not need to sell shares in the public market.

What caused the tax-withholding share disposition for Fulgent Genetics (FLGT)?

The disposition resulted from tax withholding obligations when certain restricted stock units vested. These RSUs were originally assumed under a November 7, 2022 Agreement and Plan of Merger involving Fulgent Genetics and Fulgent Pharma Holdings, as referenced in the Form 4 footnote.